<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584177</url>
  </required_header>
  <id_info>
    <org_study_id>Study 19.27</org_study_id>
    <nct_id>NCT04584177</nct_id>
  </id_info>
  <brief_title>Arm-hand Boost Program During Inpatient Rehabilitation After Stroke</brief_title>
  <official_title>Arm-hand Boost Program During Inpatient Rehabilitation After Stroke: Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jessa Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot cross-over RCT including participants with sub-acute stroke is conducted in an&#xD;
      inpatient rehabilitation setting. The experimental group (EG) receives an arm-hand boost&#xD;
      program on top of their usual care program. The control group (CG) receives a dose-matched&#xD;
      program of strengthening exercises for the lower limbs and general reconditioning. After 4&#xD;
      weeks, a cross-over is performed. Before, after 4 weeks and after 8 weeks of additional&#xD;
      therapy, different clinical outcome measures for the upper limb are administered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Actual">November 3, 2020</completion_date>
  <primary_completion_date type="Actual">November 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Fugl-Meyer Assessment-Upper Extremity at 4 weeks</measure>
    <time_frame>Between baseline and first 4 weeks of study</time_frame>
    <description>UL assessment - Function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Fugl-Meyer Assessment-Upper Extremity at 8 weeks</measure>
    <time_frame>Between baseline and end of study (=8 weeks)</time_frame>
    <description>UL assessment - Function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Action Research Arm Test at 4 weeks</measure>
    <time_frame>Between baseline and first 4 weeks of study</time_frame>
    <description>UL Assessment - Activities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Action Research Arm Test at 8 weeks</measure>
    <time_frame>Between baseline and end of study (=8 weeks)</time_frame>
    <description>UL Assessment - Activities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Jebsen Taylor hand function test at 4 weeks</measure>
    <time_frame>Between baseline and first 4 weeks of study</time_frame>
    <description>UL Assessment - Activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Jebsen Taylor hand function test at 8 weeks</measure>
    <time_frame>Between baseline and end of study (=8 weeks)</time_frame>
    <description>UL Assessment - Activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Rivermead Motor Assessment Arm function at 4 weeks</measure>
    <time_frame>Between baseline and first 4 weeks of study</time_frame>
    <description>UL Assessment - Activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Rivermead Motor Assessment Arm function at 8 weeks</measure>
    <time_frame>Between baseline and end of study (=8 weeks)</time_frame>
    <description>UL Assessment - Activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Stroke upper limb capacity scale (SULCS) at 4 weeks</measure>
    <time_frame>Between baseline and first 4 weeks of study</time_frame>
    <description>UL Assessment - Activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Stroke upper limb capacity scale (SULCS) at 8 weeks</measure>
    <time_frame>Between baseline and end of study (=8 weeks)</time_frame>
    <description>UL Assessment - Activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Box &amp; Block test at 4 weeks</measure>
    <time_frame>Between baseline and first 4 weeks of study</time_frame>
    <description>UL Assessment - Activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Box &amp; Block test at 8 weeks</measure>
    <time_frame>Between baseline and end of study (=8 weeks)</time_frame>
    <description>UL Assessment - Activities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Arm-hand BOOST + Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First 4 weeks arm-hand boost program, afterwards, 4 weeks of control program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control + Arm-hand BOOST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First 4 weeks control program, afterwards 4 weeks arm-hand boost program</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Arm-hand BOOST program</intervention_name>
    <description>The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60Â° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.</description>
    <arm_group_label>Arm-hand BOOST + Control</arm_group_label>
    <arm_group_label>Control + Arm-hand BOOST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control program</intervention_name>
    <description>A dose-matched program of strengthening exercises for the lower limbs and general reconditioning</description>
    <arm_group_label>Arm-hand BOOST + Control</arm_group_label>
    <arm_group_label>Control + Arm-hand BOOST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  first stroke, as defined by WHO,&#xD;
&#xD;
          -  minimal stay of 4 weeks in inpatient setting at study start&#xD;
&#xD;
          -  minimally 18 years old&#xD;
&#xD;
          -  being able to sit independently (trunk control test, item 3 = 25),&#xD;
&#xD;
          -  motor impairment in the upper limb (Fugl-Meyer assessment, stage 2 (synergies): 8-17p,&#xD;
             or stage 2: &lt;8p combined witht stage 5 (hand): &gt;6p&#xD;
&#xD;
          -  sufficient cooperation to perform intervention and evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  musculoskeletal and/or other neurological impairments with permanent damage that may&#xD;
             hinder the study&#xD;
&#xD;
          -  subdural hematoma, tumor, encephalitis, trauma, or other that lead to similar symptoms&#xD;
             as stroke&#xD;
&#xD;
          -  severe communication, cognitive or language impairments that hinder the investigations&#xD;
&#xD;
          -  no written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Meyer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jessa Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jessa Hospital, Campus Sint-Ursula</name>
      <address>
        <city>Herk-de-Stad</city>
        <zip>3540</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

